A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Study Purpose

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

For Parts 1 and 2: 1. Has MM defined by the IMWG criteria with evidence of disease progression and:
  • - In need of additional myeloma therapy as determined by the investigator.
  • - Has previously received at least 3 lines of myeloma therapy (for example, containing an Immunomodulatory imide drug [IMiD], a proteasome inhibitor [PI], an alkylating agent, and/or an anti-CD38 as single agents or in combination).
  • - Is either refractory to or intolerant of at least 1 PI and a least 1 IMiD.
For Part 3: 1. Has MM defined by the IMWG criteria with evidence of disease progression and:
  • - In need of additional myeloma therapy as determined by the investigator.
  • - Has previously received at least 3 lines of myeloma therapy.
  • - Is refractory to at least 1 IMiD (ie, lenalidomide or pomalidomide [thalidomide excluded]), at least 1 PI (ie, bortezomib, ixazomib, or carfilzomib), and refractory to at least 1 anti-CD38 antibody (ie, daratumumab or isatuximab) and has demonstrated disease progression with the last therapy.
Participants who are primary refractory, meaning they never achieved at least a MR with any previous treatment line, are not eligible. 2. For participants in Part 2 and 3 only: Measurable disease is defined as : 1. Serum M-protein ≥500 mg/dL (≥5 g/L) 2. Urine M-protein ≥200 mg/24 hours. 3. Serum free light chain (FLC) assay, with involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal. 3. During Part 1 only, participants not meeting the above criteria for measurable disease should, at least, have measurable bone marrow plasmacytosis (greater than or equal to [≥ ] 10 percent [%]) and/or plasmacytoma (≥1 centimeter [cm] in diameter) detected by physical examination or imaging. 4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

Exclusion Criteria:

For Parts 1 and 2: 1. Has polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome, monoclonal gammopathy of unknown significance, smoldering myeloma, solitary plasmacytoma, amyloidosis, Waldenstrom macroglobulinemia or immunoglobulin M (IgM) myeloma, or lymphoplasmacytic lymphoma (LPL). 2. Who have received autologous stem cell transplant (SCT) 60 days before first infusion of modakafusp alfa or participants who have received allogeneic SCT 6 months before first infusion. Graft-versus-host disease that is active or requires ongoing systemic immunosuppression. 3. Has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE less than or equal to (≤) Grade 1 or baseline, except for sensory or motor neuropathy which should have recovered to ≤ Grade 2 or baseline. 4. Has clinical signs of central nervous system involvement of MM. For Part 3:
  • - Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection (that is, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of HBV DNA levels. Those who are PCR positive will be excluded.
  • - In addition to the above criteria, participants must not have plasma cell leukemia or have had primary refractory MM, current central nervous system involvement of MM, myelodysplastic syndrome, myeloproliferative syndrome, or have had a second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the participant is not on active anticancer therapy.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03215030
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Takeda
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Study Director
Principal Investigator Affiliation Takeda
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Canada, China, Czechia, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Republic of, Norway, Puerto Rico, Spain, Taiwan, Turkey, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Additional Details

The drug being tested in this study, and which will be given through a vein, is called modakafusp alfa (TAK-573 ) as single agent or in combination with dexamethasone. The study will determine the safety, tolerability, and efficacy of modakafusp alfa as single agent and in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM). The study consists of 3 Parts: Part 1: Dose Escalation, Part 2: Dose Expansion, Part 3: Dose Extension. The study will enroll approximately 65 participants in Part 1, 35 in Part 2, and 236 in Part 3. Participants will be assigned to one of the following treatment groups in Parts 1 and 2 of the study. Participants will be randomly assigned in Part 3 of the study as given below:

  • - Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg.
  • - Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD.
  • - Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD.
  • - Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD.
  • - Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg.
  • - Part 3 (Dose Extension): Modakafusp alfa 120 mg.
  • - Part 3 (Dose Extension): Modakafusp alfa 240 mg.
The Part 1 (Dose Escalation) portion of the study will follow a 3+3 dose escalation design to evaluate once-weekly up to 4 different schedules of administration of modakafusp alfa starting at 0.001 mg/kg for dose limiting toxicity (DLT) evaluation and to determine the maximum tolerated dose (MTD) or an optimal biological dose (OBD) for assessments in Part 2. The Part 2 (Dose Expansion) will further assess the safety profile of modakafusp alfa and its efficacy at MTD or OBD. For Part 3 (Dose Extension) participants will be randomized 1:1 to receive single-agent modakafusp alfa 120 mg or 240 mg Q4W. Parts 1 and 2 will be conducted at multiple centers in the United States. Part 3 will be conducted worldwide. The maximum treatment duration in this study is up to 12 months (Parts 1 and 2) or until disease progression (Part 3) and overall time to participate in the study is approximately up to 90 months. Participants with clinical benefit may continue treatment after sponsor approval.

Arms & Interventions

Arms

Experimental: Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg

Modakafusp alfa 0.001 up to 14 milligram per kilogram (mg/kg), infusion, intravenously (IV), once every week (Q1W) on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.

Experimental: Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD

Modakafusp alfa TBD, infusion, IV, once every 2 weeks (Q2W) on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.

Experimental: Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD

Modakafusp alfa TBD, infusion, IV, once every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.

Experimental: Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD

Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.

Experimental: Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg

Dose(s) for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive modakafusp alfa TBD as a single agent. Participants in at least 1 cohort will receive modakafusp alfa TBD and modakafusp alfa TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.

Experimental: Part 3 (Dose Extension): Modakafusp alfa 120 mg

Participants will receive modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Experimental: Part 3 (Dose Extension): Modakafusp alfa 240 mg

Participants will receive modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Interventions

Drug: - Modakafusp alfa

Modakafusp alfa intravenous infusion.

Drug: - Dexamethasone

Dexamethasone.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Highlands Oncology Group, Springdale, Arkansas

Status

Recruiting

Address

Highlands Oncology Group

Springdale, Arkansas, 72762

Site Contact

Site Contact

hog1@hogonc.com

479-936-9901

Glendale, California

Status

Recruiting

Address

Los Angeles Cancer Network - Glendale Adventist Medical Center

Glendale, California, 91204

Site Contact

Site Contact

lasika.seneviratne@lahomg.com

818-303-3150

University of California Irvine, Orange, California

Status

Not yet recruiting

Address

University of California Irvine

Orange, California, 92868

Site Contact

Site Contact

llee@uci.edu

714-456-5153

Office of James R. Berenson MD, West Hollywood, California

Status

Recruiting

Address

Office of James R. Berenson MD

West Hollywood, California, 90069

Site Contact

Site Contact

jberenson@berensononcology.com

310-623-1222

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

Status

Not yet recruiting

Address

Smilow Cancer Hospital at Yale New Haven

New Haven, Connecticut, 06520

Site Contact

Site Contact

terri.parker@yale.edu

203-833-2701

Atlanta, Georgia

Status

Recruiting

Address

Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322

Site Contact

Site Contact

jlkaufm@emory.edu

404-778-4322

Chicago, Illinois

Status

Not yet recruiting

Address

Northwestern Medicine - Northwestern Medical Group

Chicago, Illinois, 60611

Site Contact

Site Contact

s-singhal@northwestern.edu

312-695-4159

Loyola University Medical Center, Maywood, Illinois

Status

Not yet recruiting

Address

Loyola University Medical Center

Maywood, Illinois, 60153

Site Contact

Site Contact

patrick.hagen@lumc.edu

708-327-3142

Johns Hopkins Hospital, Baltimore, Maryland

Status

Recruiting

Address

Johns Hopkins Hospital

Baltimore, Maryland, 21287

Site Contact

Site Contact

cgocke2@jhmi.edu

410-955-4042

Boston Medical Center, Boston, Massachusetts

Status

Not yet recruiting

Address

Boston Medical Center

Boston, Massachusetts, 02118

Site Contact

Site Contact

rszalat@bu.edu

857-250-6914

Dana Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana Farber Cancer Institute

Boston, Massachusetts, 02215

Site Contact

Site Contact

omar_nadeem@dfci.harvard.edu

617-632-4952

Univeristy of Nebraska Medical Center, Omaha, Nebraska

Status

Recruiting

Address

Univeristy of Nebraska Medical Center

Omaha, Nebraska, 68198

Site Contact

Site Contact

sarah.holstein@unmc.edu

402-559-8500

Las Vegas, Nevada

Status

Recruiting

Address

USOR - Comprehensive Cancer Centers of Nevada - Central Valley

Las Vegas, Nevada, 89119

Site Contact

Site Contact

edwin.kingsley@usoncology.com

702-952-3400

John Theurer Cancer Center, Hackensack, New Jersey

Status

Recruiting

Address

John Theurer Cancer Center

Hackensack, New Jersey, 07601

Site Contact

Site Contact

noa.biran@hmhn.org

551-996-5234

Montefiore Medical Center, Bronx, New York

Status

Recruiting

Address

Montefiore Medical Center

Bronx, New York, 10467

Site Contact

Site Contact

nisshah@montefiore.org

718-920-4321

University of Rochester, Rochester, New York

Status

Not yet recruiting

Address

University of Rochester

Rochester, New York, 14627

Site Contact

Site Contact

blipe@kumc.edu

913-588-5059

Levine Cancer Center, Charlotte, North Carolina

Status

Recruiting

Address

Levine Cancer Center

Charlotte, North Carolina, 28402

Site Contact

Site Contact

shebli.atrash@atriumhealth.org

704-774-9322

Levine Cancer Institute - Concord, Concord, North Carolina

Status

Recruiting

Address

Levine Cancer Institute - Concord

Concord, North Carolina, 28205

Site Contact

Site Contact

shebli.atrash@atriumhealth.org

704-774-9322

Duke University Medical Center, Durham, North Carolina

Status

Recruiting

Address

Duke University Medical Center

Durham, North Carolina, 27710

Site Contact

Site Contact

yubin.kang@duke.edu

919-668-2331

Gabrail Cancer Center, Canton, Ohio

Status

Recruiting

Address

Gabrail Cancer Center

Canton, Ohio, 44718

The Ohio State University, Columbus, Ohio

Status

Recruiting

Address

The Ohio State University

Columbus, Ohio, 43210

Site Contact

Site Contact

srinivas.devarakonda@osumc.edu

614-293-7638

Oregon Health and Science University, Portland, Oregon

Status

Not yet recruiting

Address

Oregon Health and Science University

Portland, Oregon, 97239

Site Contact

Site Contact

silbermr@ohsu.edu

503-494-5304

Penn State Hershey Cancer Institute, Hershey, Pennsylvania

Status

Not yet recruiting

Address

Penn State Hershey Cancer Institute

Hershey, Pennsylvania, 17033

Site Contact

Site Contact

naik@pennstatehealth.psu.edu

408-605-5806

University of Pennsylvania, Philadelphia, Pennsylvania

Status

Recruiting

Address

University of Pennsylvania

Philadelphia, Pennsylvania, 19104

Site Contact

Site Contact

dan.vogl@uphs.upenn.edu

215-615-6508

Memphis, Tennessee

Status

Not yet recruiting

Address

Baptist Cancer Center - Memphis - Walnut Grove

Memphis, Tennessee, 38120

Site Contact

Site Contact

muhammed.raza@bmg.md

901-752-6131

Lumi Research, Houston, Texas

Status

Recruiting

Address

Lumi Research

Houston, Texas, 77002

Site Contact

Site Contact

bhavin@lumiresearch.com

281-319-8380

Huntsman Cancer Institute, Salt Lake City, Utah

Status

Not yet recruiting

Address

Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Site Contact

Site Contact

brian.mcclune@hci.utah.edu

612-624-0123

International Sites

Vancouver, British Columbia, Canada

Status

Not yet recruiting

Address

British Columbia Cancer Agency Vancouver Centre

Vancouver, British Columbia, V5Z 4E6

Juravinski Cancer Centre, Hamilton, Ontario, Canada

Status

Recruiting

Address

Juravinski Cancer Centre

Hamilton, Ontario, L8V 5C2

Site Contact

Site Contact

hira.mian@medportal.ca

1 (905) 387-9495

Victoria Hospital, London, Ontario, Canada

Status

Not yet recruiting

Address

Victoria Hospital

London, Ontario, N6A 4G5

Site Contact

Site Contact

martha.louzada@lhsc.on.ca

519-682-8500

Centre de Recherche du CHUM, Montreal, Quebec, Canada

Status

Recruiting

Address

Centre de Recherche du CHUM

Montreal, Quebec, H2X 0C1

Montreal, Quebec, Canada

Status

Not yet recruiting

Address

Sir Mortimer B. Davis Jewish General Hospital

Montreal, Quebec, H3T 1E2

Beijing Chao-Yang Hospital, Beijing, Beijing, China

Status

Not yet recruiting

Address

Beijing Chao-Yang Hospital

Beijing, Beijing, 100020

Site Contact

Site Contact

13910107759@163.com

+8601085231000

Beijing Chao-Yang Hospital, Beijing, Beijing, China

Status

Not yet recruiting

Address

Beijing Chao-Yang Hospital

Beijing, Beijing, 100040

Site Contact

Site Contact

zhangjiajia2007@sohu.com

+8618600405718

Peking University People's Hospital, Beijing, Beijing, China

Status

Not yet recruiting

Address

Peking University People's Hospital

Beijing, Beijing, 100044

Site Contact

Site Contact

jin1lu@sina.com

+8613311491805

Peking University Third Hospital, Beijing, Beijing, China

Status

Not yet recruiting

Address

Peking University Third Hospital

Beijing, Beijing, 100089

Site Contact

Site Contact

jinghm@yahoo.com

+861068964010

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Status

Not yet recruiting

Address

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060

Site Contact

Site Contact

xiazhj@sysucc.org.cn

+8613602713223

Henan Cancer Hospital, Zhengzhou, Henan, China

Status

Not yet recruiting

Address

Henan Cancer Hospital

Zhengzhou, Henan, 450003

Site Contact

Site Contact

fdation@126.com

+8613526607830

Wuhan Union Hospital, Wuhan, Hubei, China

Status

Not yet recruiting

Address

Wuhan Union Hospital

Wuhan, Hubei, 430023

Site Contact

Site Contact

suncy0618@163.com

+8615342346782

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Status

Not yet recruiting

Address

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071

Site Contact

Site Contact

zhoufuling@163.com

+8602767812888

Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

Status

Not yet recruiting

Address

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008

Site Contact

Site Contact

chenbinggcp@163.com

+862583105860

Suzhou, Jiangsu, China

Status

Not yet recruiting

Address

The First Affiliated Hospital of Soochow University - Suzhou First People's Hospital

Suzhou, Jiangsu, 215006

Site Contact

Site Contact

fuzhengzheng@suda.edu.cn

+8613962191404

Tianjin, Tianjin, China

Status

Not yet recruiting

Address

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin, 300060

Site Contact

Site Contact

tzxyklcsy@163.com

+8618622221250

Hangzhou, Zhejiang, China

Status

Not yet recruiting

Address

The First Affiliated Hospital, Zhejiang University

Hangzhou, Zhejiang, 310003

Site Contact

Site Contact

czclinicaltrial@163.com

+8613857190311

Fakultni Nemocnice Olomouc, Olomouc, Severomoravsky KRAJ, Czechia

Status

Not yet recruiting

Address

Fakultni Nemocnice Olomouc

Olomouc, Severomoravsky KRAJ, 775 20

Site Contact

Site Contact

jiri.minarik2@fnol.cz

+420588445351

Fakultni Nemocnice Brno, Brno, Czechia

Status

Not yet recruiting

Address

Fakultni Nemocnice Brno

Brno, , 625 00

Site Contact

Site Contact

pour.ludek@fnbrno.cz

+420532233645

Univerzita Karlova - 1. Lekarska Fakulta, Praha, Czechia

Status

Not yet recruiting

Address

Univerzita Karlova - 1. Lekarska Fakulta

Praha, , 128 08

Site Contact

Site Contact

spicka@cesnet.cz

+420224962527

Strasbourg, Alsace, France

Status

Not yet recruiting

Address

Institut de cancerologie Strasbourg Europe

Strasbourg, Alsace, 67200

Site Contact

Site Contact

c.sonntag@icans.eu

+33368677301

Creteil Cedex, Ile-de-france, France

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire Henri Mondor

Creteil Cedex, Ile-de-france, 91010

Site Contact

Site Contact

karim.belhadj@aphp.fr

+33149814963

Hopital Saint-Antoine, Paris Cedex 12, Ile-de-france, France

Status

Not yet recruiting

Address

Hopital Saint-Antoine

Paris Cedex 12, Ile-de-france, 75012

Site Contact

Site Contact

mohamad.mohty@inserm.fr

+33149282162

Hopital Necker-Enfants Malades, Paris, Ile-de-france, France

Status

Not yet recruiting

Address

Hopital Necker-Enfants Malades

Paris, Ile-de-france, 75015

Site Contact

Site Contact

laurent.frenzel@nck.aphp.fr

33144495292

Toulouse, Midi-pyrenees, France

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire de Toulouse Hopital Purpan

Toulouse, Midi-pyrenees, 31059

Site Contact

Site Contact

perrot.aurore@iuct-oncopole.fr

+33383153282

Hopital Saint-Vincent de Paul - Lille, Lille Cedex, NORD Pas-de-calais, France

Status

Not yet recruiting

Address

Hopital Saint-Vincent de Paul - Lille

Lille Cedex, NORD Pas-de-calais, 59020

Site Contact

Site Contact

bourgeois-emmanuelle@ghicl.net

+33320874532

Lille Cedex, NORD Pas-de-calais, France

Status

Not yet recruiting

Address

Centre Hospitalier Regional Universitaire de Lille

Lille Cedex, NORD Pas-de-calais, 59037

Site Contact

Site Contact

salomon.manier@chru-lille.fr

+33320445713

Nantes Cedex 1, PAYS DE LA Loire, France

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire Nantes - Hotel Dieu

Nantes Cedex 1, PAYS DE LA Loire, 44093

Site Contact

Site Contact

cyrille.touzeau@chu-nantes.fr

+33253482405

Poitiers, Poitou-charentes, France

Status

Not yet recruiting

Address

Centre Hospitalier Universitaire de Poitiers

Poitiers, Poitou-charentes, 86000

Site Contact

Site Contact

xavier.leleu@chu-poitiers.fr

+33549444201

Universitatsklinik Tubingen, Tuebingen, Baden-wuerttemberg, Germany

Status

Not yet recruiting

Address

Universitatsklinik Tubingen

Tuebingen, Baden-wuerttemberg, 72076

Universitatsklinikum Dusseldorf, Duesseldorf, Nordrhein-westfalen, Germany

Status

Not yet recruiting

Address

Universitatsklinikum Dusseldorf

Duesseldorf, Nordrhein-westfalen, 40225

Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany

Status

Not yet recruiting

Address

Universitatsklinikum Leipzig

Leipzig, Sachsen, 04103

Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

Status

Not yet recruiting

Address

Universitatsklinikum Hamburg-Eppendorf

Hamburg, , 20251

Site Contact

Site Contact

k.weisel@uke.de

+4940741058581

Evaggelismos General Hospital, Athens, Attica, Greece

Status

Not yet recruiting

Address

Evaggelismos General Hospital

Athens, Attica, 10676

Site Contact

Site Contact

sodeli@yahoo.com

+302132041725

Alexandra General Hospital of Athens, Athens, Attica, Greece

Status

Not yet recruiting

Address

Alexandra General Hospital of Athens

Athens, Attica, 11528

Site Contact

Site Contact

mdimop@med.uoa.gr

+302132162541

Patra, Peloponnese, Greece

Status

Not yet recruiting

Address

University Regional General Hospital of Patras

Patra, Peloponnese, 26504

Site Contact

Site Contact

argiris.symeonidis@yahoo.gr

+302613603255

Cork University Hospital, Cork, Ireland

Status

Not yet recruiting

Address

Cork University Hospital

Cork, , T12 DC4A

Site Contact

Site Contact

mykytiv.vitaliy@hse.ie

+3530214922000

Saint Vincent's University Hospital, Dublin, Ireland

Status

Not yet recruiting

Address

Saint Vincent's University Hospital

Dublin, , D04 T6F4

Site Contact

Site Contact

k.fadalla@st-vincents.ie

+35312774000

Mater Misericordiae University Hospital, Dublin, Ireland

Status

Not yet recruiting

Address

Mater Misericordiae University Hospital

Dublin, , D07 R2WY

Site Contact

Site Contact

pogorman@materprivate.ie

+353018500977

National University of Ireland Galway, Galway, Ireland

Status

Not yet recruiting

Address

National University of Ireland Galway

Galway, , H91 TK 33

The Chaim Sheba Medical Center, Ramat Gan, Tel Aviv, Israel

Status

Not yet recruiting

Address

The Chaim Sheba Medical Center

Ramat Gan, Tel Aviv, 52621

Site Contact

Site Contact

hila.magen@shebahealth.gov.il

050-406-5462

Hadassah Medical Center, Jerusalem, Israel

Status

Not yet recruiting

Address

Hadassah Medical Center

Jerusalem, , 9112001

Site Contact

Site Contact

rmoshg@hadassah.org.il

+97226776685

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Status

Not yet recruiting

Address

Tel Aviv Sourasky Medical Center

Tel Aviv, , 6423906

Site Contact

Site Contact

yaelcoh@tlvmc.gov.il

+97236972521

AON SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Status

Not yet recruiting

Address

AON SS Antonio e Biagio e Cesare Arrigo

Alessandria, , 15121

Ancona, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona

Ancona, , 60126

Bologna, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant'Orsola-Malpighi

Bologna, , 40138

Site Contact

Site Contact

michele.cavo@unibo.it

+390516363111

Catania, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele

Catania, , 95125

Site Contact

Site Contact

diraimon@unict.it

+390957431111

Padova, Italy

Status

Not yet recruiting

Address

Department of Medicine (DIMED) Hematology and Clinical Immunology

Padova, , 35128

Site Contact

Site Contact

r.zambello@unipd.it

393488720396

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Status

Not yet recruiting

Address

Fondazione IRCCS Policlinico San Matteo

Pavia, , 27100

Site Contact

Site Contact

s.mangiacavalli@smatteo.pv.it

+39 0382503595

Nagoya City University Hospital, Nagoya, Aichi, Japan

Status

Not yet recruiting

Address

Nagoya City University Hospital

Nagoya, Aichi, 467-8601

Site Contact

Site Contact

iida@med.nagoya-cu.ac.jp

+81528515511

Ogaki Municipal Hospital, Gifu-shi, Gifu, Japan

Status

Not yet recruiting

Address

Ogaki Municipal Hospital

Gifu-shi, Gifu, 503-8502

Site Contact

Site Contact

h-kosugi@umin.ac.jp

+81 584-81-3341

Kyoto-City, Kyoto, Japan

Status

Not yet recruiting

Address

University Hospital - Kyoto Preferctural University of Medicine

Kyoto-City, Kyoto, 602-8566

Site Contact

Site Contact

junkuro@koto.kpu-m.ac.jp

+81752515740

Okayama-city, Okayama, Japan

Status

Not yet recruiting

Address

National Hospital Organization Okayama Medical Center

Okayama-city, Okayama, 701-1192

Site Contact

Site Contact

kazusuna@pop12.odn.ne.jp

+81862949911

Yamanashi Prefectural Central Hospital, Chuo-shi, Yamanasi, Japan

Status

Not yet recruiting

Address

Yamanashi Prefectural Central Hospital

Chuo-shi, Yamanasi, 409-3898

Site Contact

Site Contact

m-iino2a@ych.pref.yamanashi.jp

+81552537111

Japanese Red Cross Medical Center, Tokyo, Japan

Status

Not yet recruiting

Address

Japanese Red Cross Medical Center

Tokyo, , 150-8935

Site Contact

Site Contact

i.s.h.i.28@rondo.ocn.ne.jp

+81 3-3400-1311

Hwasun, Jeollanam-do, Korea, Republic of

Status

Not yet recruiting

Address

Chonnam National University Hwasun Hospital

Hwasun, Jeollanam-do, 58128

Site Contact

Site Contact

drjejung@chonnam.ac.kr

+82613797638

Seoul National University Hospital, Seoul, Korea, Republic of

Status

Not yet recruiting

Address

Seoul National University Hospital

Seoul, , 03080

Site Contact

Site Contact

go01@snu.ac.kr

+82320723079

Seoul, Korea, Republic of

Status

Not yet recruiting

Address

The Catholic University of Korea - Seoul St. Mary's Hospital

Seoul, , 06591

Site Contact

Site Contact

ckmin@catholic.ac.kr

+82222586053

Oslo, Norway

Status

Not yet recruiting

Address

Oslo Universitetssykehus-Ulleval Hospital

Oslo, , 0450

Site Contact

Site Contact

fredrikschjesvold@gmail.com

+4799697796

Ad-Vance Medical Research, Ponce, Puerto Rico

Status

Recruiting

Address

Ad-Vance Medical Research

Ponce, , 00730

Site Contact

Site Contact

valvarezadm@gmail.com

7872597807

Hospital Espanol Auxilio Mutuo, San Juan, Puerto Rico

Status

Recruiting

Address

Hospital Espanol Auxilio Mutuo

San Juan, , 00919

Site Contact

Site Contact

cabanillas@auxilio.com

78775820003503

Badalona, Barcelona, Spain

Status

Not yet recruiting

Address

Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, 08916

Site Contact

Site Contact

aoriol@iconcologia.net

+34934978987

Hospital Universitari Vall d'Hebron, Barcelona, Spain

Status

Not yet recruiting

Address

Hospital Universitari Vall d'Hebron

Barcelona, , 08035

Site Contact

Site Contact

mgironel@gmail.com

+34934893000

Hospital Clinic de Barcelona, Barcelona, Spain

Status

Recruiting

Address

Hospital Clinic de Barcelona

Barcelona, , 08036

Site Contact

Site Contact

lrosinol@clinic.cat

+34932275707

Hospital Universitario 12 de Octubre, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario 12 de Octubre

Madrid, , 28041

Site Contact

Site Contact

rafa_alonsofdez@yahoo.es

+34913908570

Murcia, Spain

Status

Not yet recruiting

Address

Hospital Universitario Virgen de la Arrixaca

Murcia, , 30120

Site Contact

Site Contact

mjmobel9@hotmail.com

34968369532

Hospital Universitario de Salamanca, Salamanca, Spain

Status

Recruiting

Address

Hospital Universitario de Salamanca

Salamanca, , 37007

Site Contact

Site Contact

mvmateos@usal.es

+34923291316

Santander, Spain

Status

Recruiting

Address

Hospital Universitario Marques de Valdecilla

Santander, , 39008

Site Contact

Site Contact

ocioem@unican.es

+34608429141

Tri-Service General Hospital, Taipei, Taipei CITY, Taiwan

Status

Not yet recruiting

Address

Tri-Service General Hospital

Taipei, Taipei CITY, 11490

Site Contact

Site Contact

dms1201@gmail.com

+886287927208

National Taiwan University Hospital, Taipei, Taiwan

Status

Not yet recruiting

Address

National Taiwan University Hospital

Taipei, , 100

Site Contact

Site Contact

syhuang55@ntuh.gov.tw

+88622312345663575

Taipei Veterans General Hospital, Taipei, Taiwan

Status

Not yet recruiting

Address

Taipei Veterans General Hospital

Taipei, , 11217

Site Contact

Site Contact

metalmanko2@hotmail.com

+8862287121212201

Ankara Universitesi, Yenimahalle, Ankara, Turkey

Status

Not yet recruiting

Address

Ankara Universitesi

Yenimahalle, Ankara, 06560

Site Contact

Site Contact

mbeksac56@gmail.com

+904445946

Üsküdar, Istanbul, Turkey

Status

Not yet recruiting

Address

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi

Üsküdar, Istanbul, 34664

Site Contact

Site Contact

tfiratli@hotmail.com

+9002166510000

Ondokuz Mayis Universitesi Tp Fakultesi, Samsun, Turkey

Status

Not yet recruiting

Address

Ondokuz Mayis Universitesi Tp Fakultesi

Samsun, , 55139

Site Contact

Site Contact

turgutmehmet@yahoo.com

+905324412859

Birmingham, England, United Kingdom

Status

Not yet recruiting

Address

University Hospitals Birmingham NHS Foundation Trust

Birmingham, England, B9 5SS

The Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom

Status

Not yet recruiting

Address

The Leeds Teaching Hospitals NHS Trust

Leeds, England, LS9 7TF

Site Contact

Site Contact

g.cook@leeds.ac.uk

+441132693939

London, England, United Kingdom

Status

Not yet recruiting

Address

University College London Hospitals NHS Foundation Trust

London, England, NW1 2BU

Site Contact

Site Contact

rakesh.popat@ucl.ac.uk

+448451555000

London, England, United Kingdom

Status

Not yet recruiting

Address

King's College Hospital NHS Foundation Trust

London, England, SE5 9RS

Site Contact

Site Contact

reubenbenjamin@nhs.net

+4402032999000

Manchester, England, United Kingdom

Status

Not yet recruiting

Address

The Christie - The Christie NHS Foundation Trust

Manchester, England, M20 4BX

Site Contact

Site Contact

emma.searle9@nhs.net

01619187224

Nottingham, England, United Kingdom

Status

Not yet recruiting

Address

Nottingham University Hospitals NHS Trust

Nottingham, England, NG5 1PB

Oxford, England, United Kingdom

Status

Not yet recruiting

Address

Oxford University Hospitals NHS Foundation Trust

Oxford, England, OX3 7LE

Site Contact

Site Contact

kramasamy@nhs.net

+4401865235882

The Royal Marsden NHS Foundation Trust, Sutton, England, United Kingdom

Status

Not yet recruiting

Address

The Royal Marsden NHS Foundation Trust

Sutton, England, SM2 5PT

Site Contact

Site Contact

martin.kaiser@icr.ac.uk

+442087224130

Windsor, England, United Kingdom

Status

Not yet recruiting

Address

Genesis Care Windsor - Genesis Care UK Ltd.

Windsor, England, SL43HD

Site Contact

Site Contact

jaimal.kothari@genesiscare.co.uk

07989474250